In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OncoMed Pharmaceuticals, Inc.

http://www.oncomed.com

Latest From OncoMed Pharmaceuticals, Inc.

Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022

In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.

Medical Device Cardiology

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Deals Business Strategies

Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

Business Strategies Clinical Trials

Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds

Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.

Financing ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register